Rational Design of an Active Avidin Monomer*

Olli H. LaitinenDagger , Henri R. NordlundDagger §, Vesa P. HytönenDagger §, Sanna T. H. UotilaDagger , Ari T. MarttilaDagger , Janne Savolainen, Kari J. Airenne||, Oded Livnah**, Edward A. BayerDagger Dagger , Meir WilchekDagger Dagger , and Markku S. KulomaaDagger §§

From the Dagger  Department of Biological and Environmental Science and the  Department of Chemistry, P. O. Box 35, FIN-40014 University of Jyväskylä, Finland, the || A. I. Virtanen Institute, University of Kuopio, FIN-70211 Kuopio, Finland, the ** Department of Biological Chemistry, The Institute of Life Sciences, The Wolfson Centre for Applied Structural Biology, The Hebrew University of Jerusalem, Givat Ram, Jerusaleum 91904, Israel, and the Dagger Dagger  Department of Biological Chemistry, The Weizmann Institute of Science, 76100 Rehovot, Israel

Received for publication, June 12, 2002, and in revised form, November 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Homotetrameric chicken avidin that binds four molecules of biotin was converted to a monomeric form (monoavidin) by mutations of two interface residues: tryptophan 110 in the 1 right-arrow 2 interface was mutated to lysine and asparagine 54 in the 1 right-arrow 4 interface was converted to alanine. The affinity for biotin binding of the mutant decreased from Kd ~10-15 M of the wild-type tetramer to Kd ~10-7 M, which was studied by an optical biosensor IAsys and by a fluorescence spectroscopical method in solution. The binding was completely reversible. Conversion of the tetramer to a monomer results in increased sensitivity to proteinase K digestion. The antigenic properties of the mutated protein were changed, such that monoavidin was only partially recognized by a polyclonal antibody whereas two different monoclonal antibodies entirely failed to recognize the avidin monomer. This new monomeric avidin, which binds biotin reversibly, may be useful for applications both in vitro and in vivo. It may also shed light on the effect of intersubunit interactions on the binding of ligands.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Chicken avidin and bacterial streptavidin are structurally analogous proteins, which are well known for the uniquely tenacious affinity they exhibit toward their ligand biotin. This affinity is the firmest protein-ligand interaction known in nature (Kd ~10-15 M), and, under physiological conditions, the binding can essentially be considered irreversible (1). This tight interaction has been utilized during the past three decades for various applications in the life sciences to purify, probe, and target various materials both in vitro and in vivo (2).

The scientific merit of mutation studies of avidin and streptavidin has been 2-fold. On the one hand, mutations of designated residues have provided important structural and functional information regarding the native protein. On the other, the mutant proteins themselves can be of applicative value for use in avidin-biotin technology, since they frequently exhibit special and sometimes surprising binding properties or physicochemical characteristics. In this context, the affinity of the native biotin-binding protein may be too high for some applications. In some cases, for example, a reversible binding might be desired, e.g. for affinity chromatography where the facile release of biotinylated material from an avidin column is required.

Several reports have demonstrated clearly that in most cases the strong affinity of avidin or streptavidin for biotin is dependent upon the tetrameric architecture of the protein. Indeed, long before the structures of avidin (3, 4) and streptavidin (5, 6) were known, it was recognized that the avidin monomer shows a highly reduced affinity constant, which can be recovered upon conversion of the monomer to the tetrameric state (7). The crystal structures of avidin and streptavidin have revealed that the major reason for this common property of the two biotin-binding proteins is the cross-subunit insertion of a conserved tryptophan residue (Trp-110 in avidin and Trp-120 in streptavidin) from one monomer into the binding site of its neighbor. Mutation of this tryptophan in either protein has resulted in both a reduction of binding affinity toward biotin and a reduction in the stability of the tetramer (8-10).

The quaternary structure of avidin and streptavidin has long been viewed as a dimer of dimers (11) and the transition from tetramer to dimer to monomer has always been intriguing. To study the tetrameric architecture further, we have previously probed the interface interactions in avidin by site-directed mutagenesis. In one study, we mutated the critical 1 right-arrow 2 interface residue, Trp-110 of avidin and the conserved Trp-120 of streptavidin, to lysine, which led to the production of dimeric avidin and streptavidin mutants that bound biotin reversibly (8). In another study, we mutated the critical 1 right-arrow 4 interface residue, asparagine 54, to alanine, which also led to destabilization of tetramer (12). One of the surprising outcomes of that study was the production of avidin mutants that, in the absence of biotin, appeared as monomers in solution, whereas upon binding the vitamin the monomers formed stable tetramers. It was thus of interest to investigate whether the combination of these two types of mutation might lead to a stable avidin monomer.

In the present communication, we describe a monomeric avidin mutant (monoavidin), in which Trp-110 was converted to lysine and Asn-54 was mutated to alanine. The resultant mutant binds biotin specifically in a reversible manner and remains in the monomeric state even upon binding to biotin. The resultant monomeric avidin may have applicative advantages over previously described native and mutated forms of the tetrameric and dimeric avidins and streptavidins for affinity-based separations of biotinylated biomolecules.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Construction of Recombinant Baculoviruses-- A modified (Invitrogen) donor BacToBacTM Baculovirus Expression System plasmid containing the W110K mutation (8) of avidin cDNA was further mutagenized by adding an N54A substitution by the mega-primer method (13). Subcloning of the PCR-amplified insert was performed as earlier reported by Laitinen et al. (12). A recombinant baculovirus capable of producing the N54A+W110K double mutant in avidin was constructed according to the instructions of the BacToBacTM Baculovirus expression system kit.

Production and Purification of Mutant Avidin-- Mutant avidin was produced in Baculovirus-infected insect cells as described previously (14). Purification on a biotin-agarose column was performed from cell extracts grown in biotin-free medium according to Laitinen et al. (8).

Biotin-binding Assays-- Reversibility of biotin binding was determined by competitive binding to biotinylated biosensor surfaces, and the determination of binding constants for the mutant avidin to biotin were performed using an IAsys optical biosensor as reported earlier (8). Fluorescence spectroscopy measurements were performed using a PerkinElmer LS55 luminescence spectrometer. The excitation wavelength of 280 nm was used, and the emission spectra was obtained from 320 to 420 nm using 2.5 nm excitation and 17 nm emission slitwidths. An average of four scans with scan at speed 240 nm/min was used to calculate the final result. The protein concentration in this analysis was 20 nM, and the biotin was added in small volumes to final concentrations from 0.02 nM to 13 mM. The protein sample was thoroughly mixed in a cuvette with a micropipette and incubated for 5 min covered from UV light before scanning. The measurements were performed at 23 °C in phosphate-buffered saline containing 1 M NaCl. The measured spectra were integrated, and the intensities were plotted against biotin concentration. Binding curve (quenching (%) = a[Btn]/(Kd + [Btn]) + c), where a and c are scaling factors, was fitted to this data using the least square method.

Structure Analyses-- The molecular mass of the mutant was calculated from the known amino acid composition using the GCG package program Peptidesort (Genetic Computer Group, Madison, WI). SDS-PAGE, immunoblot analyses, and assays for protease sensitivity were performed according to Laitinen et al. (8). For stability analysis, protein samples were combined with sample buffer and incubated at selected temperatures for 20 min before being subjected to SDS-PAGE (15). The quaternary status of avidin and the mutant was determined by fast-protein liquid chromatography, performed on a Superdex 200 HR 10/30 (Amersham Biosciences) using a Shimadzu SCL-10A VP system controller with RF-10A xl fluorescence detector and SPD-M 10A VP diode array detector. Samples (sodium phosphate buffer, 0.65 M NaCl, pH 7.2) were applied, and chromatography was carried out at a flow rate of 0.5 ml/min.

ELISA1 Analyses-- The immunological properties of the mutant were compared with avidin by an indirect ELISA analysis as previously described in Laitinen et al. (16). ELISAs were performed using two monoclonal avidin antibodies (produced at the Institute of Medical Technology, University of Tampere, Tampere, Finland) and a polyclonal rabbit avidin antibody (produced at the Laboratory Animal Center, University of Oulu, Oulu, Finland) as primary antibodies.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Construction, Production, and Purification of the Avidin Mutant-- The W110K+N54A avidin mutant was produced in biotin-free insect cell medium as described previously (14). The mutant was purified efficiently on biotin agarose and eluted with mild acid treatment (8) to yield virtually pure mutant protein (not shown). The location of residues W110K and N54A in the avidin tetramer is shown in Fig. 1.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Ribbon diagram of the avidin tetramer. The location of the mutated residues between subunit interfaces 1 right-arrow 2 and 1 right-arrow 4 (and 3 right-arrow 4 and 2 right-arrow 3) are shown as sticks. The subunits are color-coded as follows: subunit 1, blue; subunit 2, green; subunit 3, dark red; subunit 4, gray. Tryptophans 110 of each subunit are indicated in yellow (Trp-110 of subunit 2 is located at the left side of the figure). On its right is Trp-110 of subunit 4, and at the upper part of the figure Trp-110 residues of subunits 1 and 3 are situated. Asparagines 54 are labeled in red. The Asn-54 residues of subunits 1 and 4 are located on the left side of the figure and the corresponding asparagines of subunits 2 and 3 on the right. The diagram was created using InsightII (Molecular simulatios Inc., San Diego, CA).

Biotin-binding Analyses-- Reversibility of biotin binding was studied using an IAsys apparatus. The binding of the vitamin by the W110K+N54A mutant was found to be completely reversible (Fig. 2A). The dissociation constant of mutant for the immobilized biotin was determined at ~1-3 × 10-7 M in IAsys analyses (Fig. 2B, Table I). The binding and dissociation curves were consistent with simple first-order kinetics. The resultant kinetics data were in accord with self-consistency tests described by Schuck and Minton (17) whereby dissociation constants calculated from equilibrium response data were similar to those obtained directly from the binding curves (Table I). The binding was also examined under soluble conditions by fluorescence spectroscopy monitoring the quenching of the intrinsic fluorescence due to biotin binding to avidin. Total decrease of about 45% in protein intrinsic fluorescence intensity was observed when monoavidin sample was titrated with biotin (Fig. 2C). The fitted binding curve (r2 = 0.98) gave dissociation constant of ~7.6 × 10-8 M.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 2.   Biotin-binding characteristics of the monoavidin. A, reversibility of biotin binding by monoavidin (concentration 1.5 × 10-6 M) and apparent irreversibility by avidin (concentration 3.2 × 10-7 M). B, interaction analysis of monoavidin with the biotin cuvette. Various concentrations of monoavidin were added to the biotin-coated cuvette, and the interaction was measured by IAsys. The equilibrium response (Req) is plotted versus protein concentration. The Kd of the protein is equal to the concentration at Rmax/2. C, quenching of the intrinsic fluorescence of monoavidin plotted as a function of biotin concentration. Binding curve gave half-maximal quenching at biotin concentration 7.6 × 10-8 M (r2 = 0.98). The triangle indicates the value for quenching at 13 mM concentration of biotin.

                              
View this table:
[in this window]
[in a new window]
 
Table I
IAsys biosensor data for binding of biotin to monoavidin

Structural Analyses-- The tendency of the W110K+N54A double mutant to form higher order quaternary structures (dimers, tetramers, oligomers) was studied by SDS-PAGE based assay (15). The mutant migrated as a monomer even at room temperature, both in the absence and presence of biotin (not shown). The quaternary structure status of the mutant was also determined in solution by fast-protein liquid chromatography assay. The calculated value for the monomeric peptide sequence is 14.2 kDa (~15.7 kDa including the oligosaccharide side chain). This value fits well with the estimated molecular weights both in the absence or presence of biotin (15.2 and 17.5 kDa, respectively), indicating a monomer in solution in both cases. Biotin-free and biotin-bound forms of the native protein were tetrameric (Fig. 3). Henceforth, the W110K+N54A mutant was termed monoavidin.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 3.   Gel filtration profiles of the W110K+N54A mutant, in the presence or absence of free biotin. Human immunoglobulin G (IgG, 158 kDa), avidin (63 kDa), ovalbumin (44 kDa), and B12 vitamin (B-12, 1.35 kDa) were used as molecular mass markers to calibrate the column. The logarithm of molecular mass was plotted versus Ve/Vo (Ve = elution time, Vo = void volume). Molecular mass for monoavidin (D27) was calculated according to the slope of the curve (15.2 kDA in the absence and 17.5 kDa in the presence of biotin), indicating a monomer both in the presence and absence of the ligand. On this basis, the mutant was referred to as monoavidin.

The resistance of monoavidin to proteolytic cleavage was studied by proteinase K treatment and compared with the wild-type avidin. In the absence of biotin, monoavidin was degraded within minutes, whereas the presence of the ligand had a short-lived protective effect on the mutant against the proteolytic action of proteinase K. Complete proteolysis took place within an hour, whereupon the protein was digested into small peptides. Native avidin was clearly more stable, both in the absence and especially in the presence of biotin (Fig. 4). As reported previously (18), the native protein was cleaved into two long peptides.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 4.   Proteinase K assay of monoavidin and native avidin. A, monoavidin treated with proteinase K in the presence of biotin. Samples were extracted at the indicated time intervals. Untreated monoavidin (MA) was included as a control. B, monoavidin in the absence of biotin. The same analysis was performed for native avidin in the presence (C) and in the absence (D) of excess biotin. Proteinase K treatment of the native avidin resulted in only two defined peptides, representing a single cleavage site. In contrast, monoavidin was completely digested by proteinase K into small peptides. Molecular mass markers (L) were 21.5 and 14.4 kDa (Bio-Rad).

Immunochemical Analyses-- Monoavidin was compared immunologically to native avidin by ELISA using a polyclonal and two monoclonal anti-avidin preparations. The polyclonal rabbit sera recognized monoavidin clearly weaker than native avidin and the monoclonal antibodies failed to recognize the mutant (Table II).

                              
View this table:
[in this window]
[in a new window]
 
Table II
ELISA analysis of avidin and monoavidin using anti-avidin polyclonal (rabbit) and two different monoclonal antibody preparations
Samples were analyzed after 60-min color reaction by reading the absorbances (direct reading values shown in table) at 405 nm. Bovine serum albumin was used as a negative control (not shown).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The linkage of the tetrameric architecture to the strong affinity of the avidin/streptavidin-biotin complex was first evident from biochemical studies and then confirmed by the determination of the crystal structures (3-6). In view of these findings, we and others have employed site-directed mutagenesis of avidin and/or streptavidin (8, 9, 12, 19-23), both to better understand this intimate structure-function relationship and to design mutated forms of the proteins that would exhibit interesting physicochemical or binding properties. In this context, it has been one of our expressed goals to prepare an active, reversible biotin-binding monomer of one or both proteins. Indeed, in recent work (8), we succeeded in producing a dimeric form of avidin and streptavidin that bound biotin reversibly. In another work, we developed monomeric forms of avidin that fortuitously assembled into tetramers upon binding biotin (12). The question outstanding was whether a combination of the two types of mutant would lead to a stable, reversible biotin-binding monomer.

The dimeric mutants of avidin and streptavidin were produced by rational design (8), which involved a radical point mutation of a single biotin-binding residue (i.e. Trp-110 in avidin or the conserved Trp-120 in streptavidin) to a lysine in both cases. The rationale for this particular "irrational" mutation was inspired by comparing the sequences of avidin and streptavidin to those of the sea urchin fibropellins (24). One of the domains of the latter proteins is remarkably similar to avidin and streptavidin, including most, but not all, of the biotin-binding residues. In this case, the designated binding site tryptophan in the avidins is replaced by a lysine in the fibropellins, hence our decision to effect the Trp right-arrow Lys mutations of avidin and streptavidin. Since the same tryptophan also plays a crucial role in the 1 right-arrow 2 monomer-monomer interface, this radical type of point mutation also generates dimeric forms of the two proteins.

The monomeric avidin mutants were also produced by rational design upon categorizing the molecular forces involved in maintaining the other two interfaces of the avidin tetramer.2 Using this approach, all three residues involved in the 1 right-arrow 3 interface were converted to alanines (12). The resultant 1 right-arrow 3 mutant still formed a tetramer, but its stability properties were compromised. In contrast to the relatively weak 1 right-arrow 3 intermonomer interaction, the 1 right-arrow 4 interface exhibits an extensive hydrogen bonding network. Nevertheless, one of the residues involved in this interface (Asn-54) contributes numerous hydrogen bonding interactions with several residues of the neighboring monomer. The combination of the single Asn-54 right-arrow Ala mutation with those of the 1 right-arrow 3 interface was sufficient to disrupt the stable avidin tetramer into monomer (12). Such monomers, however, re-assembled into stable tetramers upon biotin binding.

In the present work, combined single point mutations of two critical 1 right-arrow 2 and 1 right-arrow 4 interface residues generated a stable avidin monomer. These data infer that once these two interfaces are disrupted, the relatively weak 1 right-arrow 3 interface is insufficient to maintain a viable avidin dimer. Disruption of the 1 right-arrow 2 and right-arrow 4 intermonomer interactions apparently causes changes in the tertiary structure of the avidin monomer, since the monomer is more labile than the tetramer to protease K treatment. In the conditions where proteinase K cleaves wild-type avidin at only one position (18), monoavidin was completely digested into small peptides. Moreover, immuochemical analysis using polyclonal anti-avidin antibodies revealed a reduction of cross-reactivity with monoavidin, and monoclonal antibodies (elicited against the native avidin tetramer) failed to react with the avidin monomer.

Monomeric avidin columns have been described in the past for isolation of biotinylated materials. The immobilized monomers were produced by treating native egg-white avidin columns with strong chemical denaturants (7, 25, 26). However, the avidin monomers tend to form tetramers spontaneously, despite the fact that the immobilized monomers are covalently bound to the resin (7). Once formed, the tetramers again bind biotin irreversibly. To preserve the reversibility of such columns, they are commonly stored in the presence of denaturant, but the long term utility of the column is thus compromised. The stable monoavidin described in the present communication provides a more effective and advantageous component for such columns. In addition, strategies for producing avidin-based fusion proteins would benefit from the use of monomeric avidin as a fusion partner, compared with using avidin tetramers. If a fusion partner (like avidin or streptavidin) has an intrinsic propensity toward oligomerization, the mature fusion protein would likely form higher order aggregates with undesirable physicochemical properties that would interfere with their intended function. It is not surprising that, to date, the most successful (strept)avidin-containing fusion proteins have included relatively small proteins as fusion partners, such as hevein fused to avidin (27, 28) or antibody Fab fragments fused to streptavidin (29).

The reversible biotin-binding characteristics of monoavidin are also advantageous for isolation of monoavidin-containing fusion proteins. To date, the most popular affinity purification protocols for avidin have utilized 2-iminobiotin as an affinity matrix. The relevant protocols include a binding step under conditions of high pH (>10), whereas the elution step is accomplished by lowering the pH to 4 or even lower values (30). Many proteins, however, are labile at high or low pH values, and purification procedures that include such conditions may lead to inactive fusion products. Consequently, the reversible biotin- binding properties of monoavidin are amenable to protocols that require physiological binding conditions and mild elution with biotin.

Pérez-Luna et al. (31) have recently studied the wild-type and two tetrameric streptavidin mutants by surface plasmon resonance optical biosensor. They observed that dissociation rates for these streptavidins did not follow the simple first-order kinetics in their experimentation. The reasons for this behavior were proposed to be nonspecific interactions of the bound proteins for non-evenly organized surface, cooperativity of binding to a dense biotin surface caused by multiple binding sites in tetrameric proteins, and/or interactions between adsorbed proteins and tethering effects of the ligand. In contrast, first-order association and dissociation kinetics were obtained for monoavidin using IAsys in the present study. Together with the complete reversibility of biotin binding, the data suggest that the latter phenomena did not significantly affect the observed interactions. Indeed, the lack of cooperativity would not be surprising due to the monovalency of the studied molecule. The character of the surface used for these experiments can also have a strong impact on the kinetic parameters. Edwards et al. (32) have compared the binding kinetics of human serum albumin to an antibody immobilized either to a dextran matrix or to an aminosilane surface. They found that when the dextran matrix was used the binding phenomena followed second-order kinetics due to steric hindrance between the binding matrix and the analyte, whereas kinetics obtained by using the aminosilane surface followed first-order kinetics. In this context, the binding analyses were performed on a planar aminosilane surface in the present study.

Kohanski and Lane (25) have previously described association and dissociation values for column-immobilized monomeric avidins (generated from egg white avidin by incubation with chaotropic agents) using radiolabeled biotin. The resultant on and off rates as well as the derived dissociation constant were remarkably similar to those obtained in the present work for monoavidin. In addition comparable affinity constant was determined for monoavidin under soluble conditions using fluorescence spectrophotometry. Finally, similar association and dissociation rates have recently been reported for monomeric streptavidin mutants (23).

In conclusion, the current study demonstrates how the use of the rational mutagenesis can be used to disrupt the extraordinary stability of the avidin tetramer in producing functional monomers by changing only two structurally important amino acids. The resultant monoavidin is appropriate as a reversible biotin-binding component of affinity columns and fusion proteins for use in developing novel applications of the (strept) avidin-biotin system.

    ACKNOWLEDGEMENTS

We thank Irene Helkala and Anne Ettala, Satu Pekkala, Piia Karisola, Jarno Hörhä, and Tikva Kulik for expert technical assistance.

    FOOTNOTES

* This work was supported by grants from the Academy of Finland and the Israel Science Foundation (administered by the Israel Academy of Sciences and Humanities, Jerusalem, Israel).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

§§ To whom correspondence should be addressed: Dept. of Biological and Environmental Science, P. O. Box 35 (YAB), FIN-40014 University of Jyväskylä, Finland. Tel.: 358-14-2602272; Fax: 358-14-2602221; E-mail: kulomaa@csc.fi.

Published, JBC Papers in Press, November 27, 2002, DOI 10.1074/jbc.M205844200

2 O. Livnah and E. A. Bayer, unpublished results.

    ABBREVIATIONS

The abbreviation used is: ELISA, enzyme-linked immunosorbent assay.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Green, M. (1990) Methods Enzymol. 184, 51-67[Medline] [Order article via Infotrieve]
2. Wilchek, M., and Bayer, E. A. (1999) Biomol. Eng. 16, 1-4[CrossRef][Medline] [Order article via Infotrieve]
3. Livnah, O., Bayer, E. A., Wilchek, M., and Sussman, J. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5076-5080[Abstract]
4. Pugliese, L., Coda, A., Malcovati, M., and Bolognesi, M. (1993) J. Mol. Biol. 231, 698-710[CrossRef][Medline] [Order article via Infotrieve]
5. Weber, P. C., Ohlendorf, D. H., Wendoloski, J. J., and Salemme, F. R. (1989) Science 243, 85-88[Medline] [Order article via Infotrieve]
6. Hendrickson, W. A., Pähler, A., Smith, J. L., Satow, Y., Merritt, E. A., and Phizackerley, R. P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 2190-2194[Abstract]
7. Green, N. M., and Toms, E. J. (1973) Biochem. J. 133, 687-700[Medline] [Order article via Infotrieve]
8. Laitinen, O. H., Airenne, K. J., Marttila, A. T., Kulik, T., Porkka, E., Bayer, E. A., Wilchek, M., and Kulomaa, M. S. (1999) FEBS Lett. 461, 52-58[CrossRef][Medline] [Order article via Infotrieve]
9. Sano, T., and Cantor, C. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3180-3184[Abstract]
10. Chilkoti, A., Tan, P. H., and Stayton, P. S. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1754-1758[Abstract]
11. Kurzban, G. P., Bayer, E. A., Wilchek, M., and Horowitz, P. M. (1991) J. Biol. Chem. 266, 14470-14477[Abstract/Free Full Text]
12. Laitinen, O. H., Marttila, A. T., Airenne, K. J., Kulik, T., Livnah, O., Bayer, E. A., Wilchek, M., and Kulomaa, M. S. (2001) J. Biol. Chem. 276, 8219-8224[Abstract/Free Full Text]
13. Sarkar, G., and Sommer, S. S. (1990) BioTechniques 8, 404-407[Medline] [Order article via Infotrieve]
14. Airenne, K. J., Oker-Blom, C., Marjomäki, V. S., Bayer, E. A., Wilchek, M., and Kulomaa, M. S. (1997) Protein Expression Purif. 9, 100-108[CrossRef][Medline] [Order article via Infotrieve]
15. Bayer, E. A., Ehrlich-Rogozinski, S., and Wilchek, M. (1996) Electrophoresis 17, 1319-1324[Medline] [Order article via Infotrieve]
16. Laitinen, O. H., Hytönen, V. P., Ahlroth, M. K., Pentikäinen, O. T., Gallagher, C., Nordlund, H. R., Ovod, V., Marttila, A. T., Porkka, E., Heino, S., Johnson, M. S., Airenne, K. J., and Kulomaa, M. S. (2002) Biochem. J. 363, 609-617[CrossRef][Medline] [Order article via Infotrieve]
17. Schuck, P., and Minton, A. P. (1996) Trends Biochem. Sci. 21, 458-460[CrossRef][Medline] [Order article via Infotrieve]
18. Ellison, D., Hinton, J., Hubbard, S. J., and Beynon, R. J. (1995) Protein Sci. 4, 1337-1345[Abstract/Free Full Text]
19. Marttila, A. T., Airenne, K. J., Laitinen, O. H., Kulik, T., Bayer, E. A., Wilchek, M., and Kulomaa, M. S. (1998) FEBS Lett. 441, 313-317[CrossRef][Medline] [Order article via Infotrieve]
20. Marttila, A. T., Laitinen, O. H., Airenne, K. J., Kulik, T., Bayer, E. A., Wilchek, M., and Kulomaa, M. S. (2000) FEBS Lett. 467, 31-36[CrossRef][Medline] [Order article via Infotrieve]
21. Freitag, S., Le, Trong, I., Klumb, L. A., Chu, V., Chilkoti, A., Stayton, P. S., and Stenkamp, R. E. (1999) Biomol. Eng. 16, 13-19[CrossRef][Medline] [Order article via Infotrieve]
22. Sano, T., Vajda, S., Smith, C. L., and Cantor, C. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6153-6158[Abstract/Free Full Text]
23. Qureshi, M. H., Yeung, J. C., Wu, S. C., and Wong, S. L. (2001) J. Biol. Chem. 276, 46422-46428[Abstract/Free Full Text]
24. Bisgrove, B. W., Andrews, M. E., and Raff, R. A. (1995) J. Mol. Evol. 41, 34-45[Medline] [Order article via Infotrieve]
25. Kohanski, R. A., and Lane, M. D. (1990) Methods Enzymol. 184, 194-200[Medline] [Order article via Infotrieve]
26. Henrikson, K. P., Allen, S. H. G., and Maloy, W. L. (1979) Anal. Biochem. 94, 366-370[Medline] [Order article via Infotrieve]
27. Airenne, K. J., Laitinen, O. H., Alenius, H., Mikkola, J., Kalkkinen, N., Arif, S. A., Yeang, H. Y., Palosuo, T., and Kulomaa, M. S. (1999) Protein Expression Purif. 17, 139-145[CrossRef][Medline] [Order article via Infotrieve]
28. Karisola, P., Alenius, H., Mikkola, J., Kalkkinen, N., Helin, J., Pentikainen, O. T., Repo, S., Reunala, T., Turjanmaa, K., Johnson, M. S., Palosuo, T., and Kulomaa, M. S. (2002) J. Biol. Chem. 277, 22656-22661[Abstract/Free Full Text]
29. Schultz, J., Lin, Y., Sanderson, J., Zuo, Y., Stone, D., Mallett, R., Wilbert, S., and Axworthy, D. (2000) Cancer Res. 60, 6663-6669[Abstract/Free Full Text]
30. Fudem-Goldin, B., and Orr, G. A. (1990) Methods Enzymol. 184, 167-173[Medline] [Order article via Infotrieve]
31. Pérez-Luna, V. H., O'Brien, M. J., Opperman, K. A., Hampton, P. D., López, G. P., Klumb, L. A., and Stayton, P. S. (1999) J. Am. Chem. Soc. 121, 6469-6478[CrossRef]
32. Edwards, P. R., Gill, A., Pollard-Knight, D. V., Hoare, M., Buckle, P. E., Lowe, P. A., and Leatherbarrow, R. J. (1995) Anal. Biochem. 231, 210-217[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.